☆ 4.8 Article

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

CIRCULATION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea

Kazunori Omote et al.

Summary: This study aimed to investigate the association between central hemodynamic abnormalities during rest and exercise and adverse clinical outcomes in patients with dyspnea. The results showed that increased exercise pulmonary artery wedge pressure (PAWP) and elevated resting PAWP were associated with higher risk of events in heart failure with preserved ejection fraction (HFpEF) patients. These findings suggest that treatment strategies that reduce central pressures and improve cardiac output reserve may have the greatest potential to improve outcomes in HFpEF.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Barry A. Borlaug et al.

Summary: Obesity and heart failure with preserved ejection fraction (HFpEF) are two intertwining epidemics, and obesity may have widespread effects on the cardiovascular system, leading to symptomatic HFpEF. Understanding the pathophysiological mechanisms of obese HFpEF is crucial for developing new therapeutic approaches.

CARDIOVASCULAR RESEARCH (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Jan Biegus et al.

Summary: This study evaluated the decongestion effects of empagliflozin in patients with acute heart failure (AHF) and found that compared to placebo, empagliflozin significantly reduced markers of decongestion at all time-points. Patients with greater weight loss within the first 15 days showed higher clinical benefit at Day 90.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Emil Wolsk et al.

Summary: Treatment with empagliflozin, an SGLT-2 inhibitor, significantly reduces cardiovascular events in patients with type 2 diabetes. However, the mechanisms behind this reduction are still unknown. A randomized, placebo-controlled, double-blinded trial was conducted to investigate the effects of SGLT-2i treatment on central hemodynamics during rest and exercise in 34 patients with diabetes. The results showed that empagliflozin did not significantly reduce left heart filling pressure at submaximal exercise but had a clinically significant reduction in pulmonary capillary wedge pressure at rest.

DIABETES (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

Milton Packer

Summary: SGLT2 inhibitors promote cellular housekeeping and enhance cellular protection, leading to reduced progression of cardiomyopathy and nephropathy. Clinical studies suggest that SGLT2 inhibitors enhance nutrient deprivation signaling, resulting in a lower risk of heart failure and serious renal events.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

Faiez Zannad et al.

Summary: The study revealed that empagliflozin has significant effects on circulating protein levels in heart failure patients, potentially improving cardiovascular outcomes by promoting autophagic flux, nutrient deprivation signaling, and transmembrane sodium transport in the heart and kidneys.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Carly Adamson et al.

Summary: Obesity is common in HFpEF patients and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure Results From the EMBRACE-HF Trial

Michael E. Nassif et al.

Summary: The EMBRACE-HF trial showed that empagliflozin significantly reduced pulmonary artery diastolic pressure in patients with heart failure, with effects increasing over time and appearing to be independent of loop diuretic management.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure

Wayne L. Miller et al.

Summary: The study showed that elevated cardiac filling pressures in heart failure patients may be related to abnormalities in cardiac diastolic function and intravascular volume. Some patients with increased volume still displayed normal hemodynamic parameters, while others with normal volume showed elevated filling pressures.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif et al.

Summary: In a randomized trial, the SGLT2 inhibitor dapagliflozin significantly improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF) over a 12-week period, which can lead to an enhanced quality of life for these patients.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects

Matthew Griffin et al.

CIRCULATION (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Martin R. Cowie et al.

NATURE REVIEWS CARDIOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Altered Hemodynamics and End-Organ Damage in Heart Failure Impact on the Lung and Kidney

Frederik H. Verbrugge et al.

CIRCULATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction

Massar Omar et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction JACC State-of-the-Art Review

Ambarish Pandey et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review

Gary D. Lopaschuk et al.

JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Heart Failure With Preserved Ejection Fraction In Perspective

Marc A. Pfeffer et al.

CIRCULATION RESEARCH (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Burkert Pieske et al.

EUROPEAN HEART JOURNAL (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction

Yogesh N. V. Reddy et al.

EUROPEAN HEART JOURNAL (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure

Aaron S. Eisman et al.

CIRCULATION-HEART FAILURE (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction

Masaru Obokata et al.

EUROPEAN HEART JOURNAL (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction

Yogesh N. V. Reddy et al.

JACC-HEART FAILURE (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure

Ambarish Pandey et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction

Barry A. Borlaug et al.

CIRCULATION RESEARCH (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction

Barry A. Borlaug et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction

Stephan Dorfs et al.

EUROPEAN HEART JOURNAL (2014)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The pathophysiology of heart failure with preserved ejection fraction

Barry A. Borlaug

NATURE REVIEWS CARDIOLOGY (2014)

添加到收藏夹

Article Pharmacology & Pharmacy

Bonferroni-based correction factor for multiple, correlated endpoints

Qian Shi et al.

PHARMACEUTICAL STATISTICS (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.